Ammar A Elsayed, Abbas F A Hussein, Yousef H Saad, Khaled Elbabry, Rowan H Elhalag, Fadi Eissa, Ahmed Nasr, Abdellate Khaled, Vishal Chavda, Mohammad M Khan, Bipin Chaurasia
{"title":"池神经囊虫病:疗效、安全性和结局的系统回顾和荟萃分析。","authors":"Ammar A Elsayed, Abbas F A Hussein, Yousef H Saad, Khaled Elbabry, Rowan H Elhalag, Fadi Eissa, Ahmed Nasr, Abdellate Khaled, Vishal Chavda, Mohammad M Khan, Bipin Chaurasia","doi":"10.1055/a-2642-8152","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent studies show potential benefits of albendazole in managing cisternal neurocysticercosis (NCC), which reduces parasitic burden. This systematic review and meta-analysis aim to evaluate the efficacy of albendazole and other pharmacological treatments in cisternal NCC, considering the heterogeneity of disease manifestations and the need for effective treatment strategies.</p><p><strong>Methods: </strong>Comprehensive searches were conducted across PubMed, Web of Science, Scopus, CENTRAL, and Embase up to March 2024, focusing on RCTs and observational studies that examined albendazole's impact on cisternal NCC. Data were pooled using a random-effects model, adhering to the Cochrane handbook for systematic reviews and meta-analysis and the preferred reporting items for systematic reviews and meta-analyses guidelines, to calculate relative risks (RRs) for various outcomes, including cyst resolution and side effects.</p><p><strong>Results: </strong>Eight studies with 2,001 patients treated with albendazole, comparing outcomes against placebo or no treatment. Findings indicated a statistically significant decrease in complete cyst resolution among albendazole recipients (RR = 0.69), with notable heterogeneity across studies. No significant differences were observed in persistent cysts, partial cyst resolution, seizures, nonneurological side effects, death, or calcification rates posttreatment. Adjustments for heterogeneity refined some associations, particularly with persistent cysts after excluding specific studies.</p><p><strong>Conclusion: </strong>Albendazole demonstrates potential in reducing active cysts in cisternal NCC, though its efficacy varies across different clinical outcomes, necessitating personalized treatment approaches. The observed heterogeneity and the variable impact on cyst resolution and seizures underscore the complexity of managing NCC. Further high-quality, large-scale RCTs are essential to solidify these findings and guide treatment protocols, emphasizing the need for multidisciplinary strategies in addressing this challenging condition.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":"86 3","pages":"e140-e148"},"PeriodicalIF":0.6000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255487/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cisternal Neurocysticercosis: A Systematic Review and Meta-Analysis of Therapeutic Efficacy, Safety, and Outcomes.\",\"authors\":\"Ammar A Elsayed, Abbas F A Hussein, Yousef H Saad, Khaled Elbabry, Rowan H Elhalag, Fadi Eissa, Ahmed Nasr, Abdellate Khaled, Vishal Chavda, Mohammad M Khan, Bipin Chaurasia\",\"doi\":\"10.1055/a-2642-8152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Recent studies show potential benefits of albendazole in managing cisternal neurocysticercosis (NCC), which reduces parasitic burden. This systematic review and meta-analysis aim to evaluate the efficacy of albendazole and other pharmacological treatments in cisternal NCC, considering the heterogeneity of disease manifestations and the need for effective treatment strategies.</p><p><strong>Methods: </strong>Comprehensive searches were conducted across PubMed, Web of Science, Scopus, CENTRAL, and Embase up to March 2024, focusing on RCTs and observational studies that examined albendazole's impact on cisternal NCC. Data were pooled using a random-effects model, adhering to the Cochrane handbook for systematic reviews and meta-analysis and the preferred reporting items for systematic reviews and meta-analyses guidelines, to calculate relative risks (RRs) for various outcomes, including cyst resolution and side effects.</p><p><strong>Results: </strong>Eight studies with 2,001 patients treated with albendazole, comparing outcomes against placebo or no treatment. Findings indicated a statistically significant decrease in complete cyst resolution among albendazole recipients (RR = 0.69), with notable heterogeneity across studies. No significant differences were observed in persistent cysts, partial cyst resolution, seizures, nonneurological side effects, death, or calcification rates posttreatment. Adjustments for heterogeneity refined some associations, particularly with persistent cysts after excluding specific studies.</p><p><strong>Conclusion: </strong>Albendazole demonstrates potential in reducing active cysts in cisternal NCC, though its efficacy varies across different clinical outcomes, necessitating personalized treatment approaches. The observed heterogeneity and the variable impact on cyst resolution and seizures underscore the complexity of managing NCC. Further high-quality, large-scale RCTs are essential to solidify these findings and guide treatment protocols, emphasizing the need for multidisciplinary strategies in addressing this challenging condition.</p>\",\"PeriodicalId\":44256,\"journal\":{\"name\":\"Journal of Neurological Surgery Reports\",\"volume\":\"86 3\",\"pages\":\"e140-e148\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255487/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurological Surgery Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2642-8152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurological Surgery Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2642-8152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:最近的研究显示阿苯达唑治疗池性神经囊虫病(NCC)的潜在益处,可减少寄生虫负担。本系统综述和荟萃分析旨在评估阿苯达唑和其他药物治疗池性NCC的疗效,考虑到疾病表现的异质性和有效治疗策略的需要。方法:截至2024年3月,在PubMed、Web of Science、Scopus、CENTRAL和Embase上进行综合检索,重点关注阿苯达唑对池性NCC影响的随机对照试验和观察性研究。采用随机效应模型汇总数据,遵循Cochrane系统评价和荟萃分析手册以及系统评价和荟萃分析指南的首选报告项目,计算各种结果的相对风险(rr),包括囊肿消退和副作用。结果:8项研究,2001例患者接受阿苯达唑治疗,与安慰剂或未接受治疗的结果进行比较。研究结果显示,阿苯达唑受体的囊肿完全溶解率显著降低(RR = 0.69),各研究间存在显著异质性。在持续囊肿、部分囊肿消退、癫痫发作、非神经系统副作用、死亡或治疗后钙化率方面没有观察到显著差异。对异质性的调整细化了一些关联,特别是在排除特定研究后与持续性囊肿的关联。结论:阿苯达唑显示出减少池性NCC活动性囊肿的潜力,尽管其疗效因临床结果而异,需要个性化的治疗方法。观察到的异质性和对囊肿消退和癫痫发作的不同影响强调了治疗NCC的复杂性。进一步的高质量、大规模随机对照试验对于巩固这些发现和指导治疗方案至关重要,强调需要多学科策略来解决这一具有挑战性的疾病。
Cisternal Neurocysticercosis: A Systematic Review and Meta-Analysis of Therapeutic Efficacy, Safety, and Outcomes.
Background: Recent studies show potential benefits of albendazole in managing cisternal neurocysticercosis (NCC), which reduces parasitic burden. This systematic review and meta-analysis aim to evaluate the efficacy of albendazole and other pharmacological treatments in cisternal NCC, considering the heterogeneity of disease manifestations and the need for effective treatment strategies.
Methods: Comprehensive searches were conducted across PubMed, Web of Science, Scopus, CENTRAL, and Embase up to March 2024, focusing on RCTs and observational studies that examined albendazole's impact on cisternal NCC. Data were pooled using a random-effects model, adhering to the Cochrane handbook for systematic reviews and meta-analysis and the preferred reporting items for systematic reviews and meta-analyses guidelines, to calculate relative risks (RRs) for various outcomes, including cyst resolution and side effects.
Results: Eight studies with 2,001 patients treated with albendazole, comparing outcomes against placebo or no treatment. Findings indicated a statistically significant decrease in complete cyst resolution among albendazole recipients (RR = 0.69), with notable heterogeneity across studies. No significant differences were observed in persistent cysts, partial cyst resolution, seizures, nonneurological side effects, death, or calcification rates posttreatment. Adjustments for heterogeneity refined some associations, particularly with persistent cysts after excluding specific studies.
Conclusion: Albendazole demonstrates potential in reducing active cysts in cisternal NCC, though its efficacy varies across different clinical outcomes, necessitating personalized treatment approaches. The observed heterogeneity and the variable impact on cyst resolution and seizures underscore the complexity of managing NCC. Further high-quality, large-scale RCTs are essential to solidify these findings and guide treatment protocols, emphasizing the need for multidisciplinary strategies in addressing this challenging condition.